Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Meg J JardineZien ZhouKenneth W MahaffeyMegumi OshimaRajiv AgarwalGeorge L BakrisHarpreet S BajajScott BullChristopher P CannonDavid M CharytanDick de ZeeuwGian Luca Di TannaTom GreeneHiddo J L HeerspinkAdeera LevinBruce NealCarol PollockRose QiuTao SunDavid C WheelerHong ZhangBernard ZinmanNorman RosenthalVlado Perkovicnull nullPublished in: Journal of the American Society of Nephrology : JASN (2020)
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791.